Literature DB >> 8939908

Contributions of the mitogen-activated protein (MAP) kinase backbone and phosphorylation loop to MEK specificity.

M J Robinson1, M Cheng, A Khokhlatchev, D Ebert, N Ahn, K L Guan, B Stein, E Goldsmith, M H Cobb.   

Abstract

To examine the specificity of MEKs for MAP kinase family members, we determined the abilities of several MEK isoforms to phosphorylate mutants of the MAP kinase ERK2 and the related kinase ERK3 which are modified in the phosphorylation loop. The ERK2 mutants included mutations of the two phosphorylation sites, mutations of the acidic residue between these two sites, and mutations that shorten the length of this loop. All mutants were tested for phosphorylation by six mammalian MEKs and compared with several wild type MAP kinases. MEK1 and MEK2 phosphorylate a majority of the ERK2 mutants. MEK2 but not MEK1 will phosphorylate ERK3. Alteration of the residue between the two phosphorylation sites neither dramatically affected the activity of MEK1 and MEK2 toward ERK2 nor conferred recognition by other MEKs. Likewise, reduction of the length of the phosphorylation loop only partially reduces recognition by MEK1 and MEK2 but does not promote recognition by other MEKs. Thus other yet to be identified factors must contribute to the specificity of MEK recognition of MAP kinases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939908     DOI: 10.1074/jbc.271.47.29734

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission.

Authors:  A J Bardwell; L J Flatauer; K Matsukuma; J Thorner; L Bardwell
Journal:  J Biol Chem       Date:  2000-12-28       Impact factor: 5.157

2.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells.

Authors:  Mark Cannon; Nicola J Philpott; Ethel Cesarman
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 3.  MAPK machinery in plants: recognition and response to different stresses through multiple signal transduction pathways.

Authors:  Gohar Taj; Payal Agarwal; Murray Grant; Anil Kumar
Journal:  Plant Signal Behav       Date:  2010-11-01

4.  Mechanisms of MAPK signalling specificity.

Authors:  L Bardwell
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

5.  Selectivity of docking sites in MAPK kinases.

Authors:  A Jane Bardwell; Erlynn Frankson; Lee Bardwell
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

6.  Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.

Authors:  Aritro Sen; Katherine O'Malley; Zhou Wang; Ganesh V Raj; Donald B Defranco; Stephen R Hammes
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

7.  Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase.

Authors:  J M Jacqué; A Mann; H Enslen; N Sharova; B Brichacek; R J Davis; M Stevenson
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

Review 8.  How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

Authors:  Yohannes Mebratu; Yohannes Tesfaigzi
Journal:  Cell Cycle       Date:  2009-04-11       Impact factor: 4.534

9.  Angiotensin II type 1 receptor mediates partially hyposmotic-induced increase of I (Ks) current in guinea pig atrium.

Authors:  Dimitar P Zankov; Futoshi Toyoda; Mariko Omatsu-Kanbe; Hiroshi Matsuura; Minoru Horie
Journal:  Pflugers Arch       Date:  2009-04-29       Impact factor: 3.657

10.  The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro.

Authors:  Irfan Yavasoglu; Gokhan Sargin; Gurhan Kadikoylu; Aslihan Karul; Zahit Bolaman
Journal:  Med Oncol       Date:  2013-05-19       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.